Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

• On-treatment changes in CD8+ CM cells correlate with best overall response in advanced melanoma patients.
• Alterations in CD4+ EM cell populations are also associated with patient outcomes, highlighting their importance.
• Patients receiving relatlimab showed significant immune cell changes linked to treatment efficacy.
• Insights from biomarker analyses may guide future therapeutic strategies for melanoma.